Status: Recruiting
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Participants needed: 110
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Teclison Ltd.Updated: Apr 16, 2026Locations: 3
Eligibility criteria
Liver metastatic MSS-mCRC or NSCLC without EGFR or AKT mutations [+6]
Prior organ transplantation [+5]